Opdivo revenue grew 7% to $2.5 billion in Q3 on continued demand. ・The company now expects high single-digit to low ...

Question: I paid so much for my Eliquis this year, will I have to pay that much next year too? Answer: The good news is no, seniors will not pay as much for Eliquis as well as nine other common ...

For the third quarter, Bristol Myers posted revenue of $12.22 billion, beating analysts' average estimate of $11.8 billion, according to data compiled by LSEG. On an adjusted basis, the company earned ...

Drugs that will be subject to rebates in 340B next year include Bristol Myers Squibb’s Eliquis, Johnson & Johnson’s Stelara ...

Bristol Myers Squibb Co. raised its revenue outlook for the year after newer medicines outperformed expectations, easing ...

However, sentiment ahead of Q3 appears cautious—in the past three months, EPS estimates have seen 17 downward revisions ...

Expected out of-pocket costs for commonly prescribed brand name medications have grown substantially for Medicare Part D beneficiaries as drug plans increasingly tie patient costs to list prices, ...

The deal is part of Trump's broader effort to tie the amount the government pays for certain drugs to the prices paid ...

Bristol Myers Squibb and Pfizer on Thursday said they will start selling their blockbuster blood thinner, Eliquis, directly to patients at a more than 40% discount. The move comes as the Trump ...

Bristol-Myers Squibb Company BMY reported fourth-quarter 2024 adjusted earnings per share (EPS) of $1.67, which beat the Zacks Consensus Estimate of $1.46. In the year-ago quarter, BMY posted an ...